Surmodics Inc Revenue Growth Rates (SRDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Surmodics Inc   (NASDAQ: SRDX)
 

SRDX's Revenue Growth by Quarter and Year

Surmodics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRDX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter September -
3rd Quarter June 29.57
2nd Quarter March 28.09
1st Quarter December 29.92
FY 87.58

SRDXs Annual Revenue
Surmodics Inc 's Revenue in the fiscal year 2024 $ 126.08 millions
Surmodics Inc 's Revenue in the fiscal year 2023 $ 132.58 millions
Surmodics Inc 's Revenue in the fiscal year 2022 $ 99.95 millions
Surmodics Inc 's Revenue in the fiscal year 2021 $ 105.14 millions
Surmodics Inc 's Revenue in the fiscal year 2020 $ 94.86 millions




SRDX Revenue third quarter 2025 Y/Y Growth Comment
Surmodics Inc reported decrease in Revenue in the third quarter 2025 by -2.55% to $ 29.57 millions, from the same quarter in 2024.
The decrease in the third quarter 2025 Surmodics Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 8.64%.

Looking into third quarter 2025 results within Medical Equipment & Supplies industry 119 other companies have achieved higher Revenue growth. While Surmodics Inc ' s Revenue decline of -2.55% ranks overall at the positon no. 2534 in the third quarter 2025.


SRDX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter September - 18.81 % 7.62 % 8.43 %
3rd Quarter June -2.55 % -42.19 % 111.19 % 4.11 %
2nd Quarter March -12.11 % 17.5 % 4.17 % -25.4 %
1st Quarter December -2.06 % 22.54 % 8.39 % 3.14 %
FY   - -4.9 % 32.65 % -

Financial Statements
Surmodics Inc 's third quarter 2025 Revenue $ 29.57 millions SRDX's Income Statement
Surmodics Inc 's third quarter 2024 Revenue $ 30.34 millions Quarterly SRDX's Income Statement


SRDX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter September - 9.53 % -46.7 % 4.59 %
3rd Quarter June 5.26 % -5.07 % 92.94 % -4.83 %
2nd Quarter March -6.12 % 4.62 % 9.11 % 13.52 %
1st Quarter December -9.96 % 9.22 % -4.08 % -4.05 %
FY (Year on Year)   - -4.9 % 32.65 % -


Back to SRDX Growth rate Comparisons >> Back to SRDX Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #375
Overall #2534

Revenue Y/Y Growth Statistics
High Average Low
113.94 % 8.64 % -40.24 %
(Jun 30 2024)   (Sep. 30, 2013)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #375
Overall #2534
Revenue Y/Y Growth Statistics
High Average Low
113.94 % 8.64 % -40.24 %
(Jun 30 2024)   (Sep. 30, 2013)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Surmodics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56.95 % -0.47 % -100 %
(Mar 31 2021)  


SRDX's III. Quarter Q/Q Revenue Comment
Surmodics Inc achieved in the III. Quarter 2025 above company average sequential Revenue increase of 5.26%, to $ 29.57 millions, from $28.09 millions in the second quarter.
SRDX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Surmodics Inc 's Revenue growth quarter on quarter, overall rank is 1756.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #98
Healthcare Sector #310
Overall #1756
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #98
Healthcare Sector #310
Overall #1756
Revenue Q/Q Growth Statistics
High Average Low
56.95 % -0.47 % -100 %
(Mar 31 2021)  


SRDX's III. Quarter Q/Q Revenue Comment
Surmodics Inc achieved in the III. Quarter 2025 above company average sequential Revenue increase of 5.26%, to $ 29.57 millions, from $28.09 millions in the second quarter.
SRDX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Surmodics Inc 's Revenue growth quarter on quarter, overall rank is 1756.


Surmodics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 120.80 $ 121.58 $ 125.45 $ 126.08 $ 120.82
Y / Y Revenue Growth (TTM) -0.02 % -14.96 % -9.23 % -4.91 % -7.49 %
Year on Year Revenue Growth Overall Ranking # 216 # 125 # 11 # 0 # 1376
Seqeuential Revenue Change (TTM) -0.64 % -3.09 % -0.5 % 4.35 % -15.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 1662 # 1568 # 16 # 0 # 1821


Cumulative Revenue growth Comment
Surmodics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2025. If the fiscal year would end in Jun 30 2025, Surmodics Inc 's annual Revenue fall would be -0.02% year on year to $121 millions.

In the Healthcare sector 64 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 125 to 216.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 93
Healthcare Sector # 65
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
44.16 %
 6.4 %
-71.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 265
S&P 500 # 1662
Cumulative Revenue growth Comment
Surmodics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2025. If the fiscal year would end in Jun 30 2025, Surmodics Inc 's annual Revenue drop would be -0.02% year on year to $121 millions.

In the Healthcare sector 64 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 125 to 216.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 93
Healthcare Sector # 65
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
44.16 %
6.4 %
-71.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 265
S&P 500 # 1662




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SRDX's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Surmodics Inc Revenue Growth Rates (SRDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Surmodics Inc (CIK 924717).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-25-105477
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Surmodics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.